Hydroxytyrosol Improved Artery Function in Patients with Coronary Disease

Why This Study Matters

Most research on hydroxytyrosol measures its effects through blood biomarkers -- oxidative stress, inflammation, lipid profiles. Those are useful, but they're proxies. The question that matters more to a cardiologist is: does the compound change how blood vessels actually function?

This trial went after that question directly. Researchers at Attikon University Hospital in Athens took 30 patients with chronic coronary artery syndrome -- people with established heart disease, not healthy volunteers -- and measured the physical behavior of their arteries and heart before and after treatment with hydroxytyrosol-enriched olive oil. They used ultrasound to watch arteries dilate. They measured how fast pulse waves traveled through stiffened vessels. They assessed coronary blood flow reserve and the integrity of the glycocalyx, the fragile lining inside every blood vessel.

That combination of functional vascular endpoints, in a population with real cardiovascular disease, makes this one of the more clinically direct hydroxytyrosol trials published to date. It's not measuring what might lead to arterial damage. It's measuring the arteries themselves.

How It Was Designed

The study used a crossover design, which is a meaningful methodological choice. Rather than splitting patients into two groups, every participant received both the active treatment and the placebo -- just in different order, with a washout period between. This means each person served as their own control, eliminating between-subject variability. In a 30-person trial, that matters. It gives the data more statistical power than a parallel-group design of the same size would.

The trial was double-blinded -- neither patients nor investigators knew which capsules were active during each treatment phase. Each participant took 4 capsules per day, delivering a total of 10 mg of hydroxytyrosol (from 1,650 mg of olive oil) for one month per phase. Vascular measurements were taken at baseline and after each treatment period using Doppler echocardiography and established non-invasive techniques.

One detail worth noting: the researchers didn't just measure one or two vascular endpoints. They assessed function at four levels -- microvascular (glycocalyx), conduit artery (flow-mediated dilation), central arterial (pulse wave velocity), and coronary (coronary flow reserve). That breadth is unusual for a single trial and gives a more complete picture of how the compound interacts with the vascular system.

What They Found

After one month of hydroxytyrosol-enriched olive oil, all four vascular function markers improved significantly. None changed after placebo:

Marker	After Treatment	Baseline	p-value	What It Measures
FMD	6.5%	3.7%	< 0.001	Endothelial function (artery dilation)
PWV	11.1 m/s	11.8 m/s	0.002	Arterial stiffness (lower is better)
CFR	2.5	2.3	0.030	Coronary blood flow reserve
PBR	1.7 um	1.8 um	0.040	Glycocalyx integrity (lower is better)

In parallel, treatment with hydroxytyrosol-enriched olive oil also reduced several blood-based markers:

Biomarker	Treatment	Placebo	p-value	What It Measures
Malondialdehyde	Reduced	No change	< 0.05	Lipid peroxidation
Oxidized LDL	Reduced	No change	< 0.05	LDL cholesterol oxidation
CRP	Reduced	No change	< 0.05	Systemic inflammation
Triglycerides	Reduced	No change	< 0.05	Blood fat levels
PCSK9	Reduced	No change	< 0.05	LDL receptor regulation

Green indicates a favorable direction vs. placebo. All differences are statistically significant.

Reading the Results

Endothelial function and arterial stiffness (FMD, PWV). Flow-mediated dilation measures the endothelium's ability to relax an artery in response to increased blood flow. It's one of the most widely used non-invasive tests of vascular health. The treatment group nearly doubled their FMD -- from 3.7% to 6.5% -- which is a large and clinically meaningful change. Pulse wave velocity, which measures how fast pressure waves travel through stiff arteries (higher means stiffer), dropped from 11.8 to 11.1 m/s. In patients with established coronary disease, improvements of this magnitude are notable.

Coronary flow reserve and microvascular integrity (CFR, PBR). CFR reflects the heart's ability to increase blood flow when demand rises -- during exercise, for example. A higher reserve means the coronary circulation has more capacity. PBR measures the perfused boundary region of sublingual microvessels; a smaller PBR indicates a thicker, healthier glycocalyx. The glycocalyx is the gel-like layer lining the interior of all blood vessels. It regulates permeability, prevents clotting, and mediates vasodilation. Damage to the glycocalyx is an early step in atherosclerosis. Both markers improved after treatment but not after placebo.

Oxidative stress and inflammation (malondialdehyde, oxLDL, CRP). These results suggest a mechanism behind the vascular improvements. Malondialdehyde is a byproduct of lipid peroxidation -- when cell membranes are damaged by free radicals. Oxidized LDL is the form of cholesterol that triggers plaque formation in artery walls. CRP is a broad inflammatory marker. Reductions in all three point to a combined antioxidant and anti-inflammatory effect, which aligns with the known pharmacology of hydroxytyrosol.

Lipid regulation (triglycerides, PCSK9). The reduction in PCSK9 is worth highlighting. PCSK9 is a protein that degrades LDL receptors on liver cells, reducing the body's ability to clear LDL from the blood. Pharmaceutical PCSK9 inhibitors are a major class of cholesterol-lowering drugs. Seeing a dietary polyphenol reduce PCSK9 levels, even modestly, is an interesting mechanistic finding that warrants further investigation.

Diastolic function (E', deceleration time). The trial also found improvements in two echocardiographic markers of how well the left ventricle relaxes between heartbeats. E' velocity of the mitral annulus and deceleration time of the E wave both improved with treatment but not placebo. This suggests the vascular benefits may extend to cardiac function itself -- not just the arteries feeding it.

What Didn't Change

Blood pressure was unaffected by treatment. This is worth noting because it shows the vascular improvements occurred through mechanisms other than blood pressure reduction -- likely the antioxidant and anti-inflammatory pathways reflected in the biomarker data. The study was not designed or powered to detect changes in clinical events or long-term disease progression.

Broader Context

The landmark PREDIMED trial demonstrated cardiovascular benefits from extra virgin olive oil rich in polyphenols, and in 2011 the European Food Safety Authority (EFSA) authorized a health claim for olive oil polyphenols and the protection of blood lipids from oxidative damage. But PREDIMED used whole olive oil as part of a complete dietary intervention. The question of which specific compounds drove the vascular effects has remained open.

This trial narrows the focus. By delivering hydroxytyrosol in capsule form at a defined dose to patients with existing coronary disease, it tested the polyphenol's effects on the vasculature with more specificity than dietary studies can. The crossover design, the breadth of vascular endpoints, and the clinical population all strengthen its contribution. At the same time, the sample size is small (30 patients) and the treatment period short (one month). The authors themselves note that further studies are needed to confirm the mechanisms.

What makes this study distinctive within the hydroxytyrosol literature is its focus on functional vascular outcomes rather than blood biomarkers alone. Showing that arteries actually dilate better, that pulse waves slow down, and that coronary flow reserve increases -- in patients who already have coronary artery disease -- is a different category of evidence than showing a biomarker moved in a favorable direction.

Related Research

Continue exploring olive oil and polyphenol science:

• Hydroxytyrosol Improves 7 Biomarkers of Aging and Inflammation
• Hydroxytyrosol Metabolism Linked to 56% Lower Cardiovascular Risk in 1,851 Adults
• Olive Oil and 14% Lower CV Risk in 90,000+ US Adults

Source: View the original study on PubMed

Olivea's Dosage

This trial used 10 mg/day of hydroxytyrosol. Each Olivea capsule delivers over 20 mg of hydroxytyrosol per serving. Our most recent third-party certificate of analysis confirmed 23.5 mg per capsule.

We share this research for transparency. This is an independent study -- we did not fund it, design it, or conduct it.

Editorial Information

Research note. This article summarizes third-party research published in a peer-reviewed journal. Olivea did not conduct or fund the study. Findings reflect the cited paper only and do not establish efficacy of Olivea products.

.